uniQure N.V. Ordinary Shares vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.09 (market cap $4.39B). The key difference: State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF is far larger — about 3× uniQure N.V. Ordinary Shares's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 42 Days on average.
| QURE | SJNK | |
|---|---|---|
Market Cap | $1.48B | $4.39B |
Volume | 2,488,780 | 1,736,904 |
Sector | Health | Fixed Income |
52-Week High | $70.59 | $25.57 |
52-Week Low | $9.03 | $24.10 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $728.62M | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SJNK trades at $24.19, showing minimal daily movement with a slight decline of 0.21%. The technical outlook appears bearish based on moving averages, though oscillators suggest neutral conditions. Recent corporate actions include consistent dividend payments, with three distributions scheduled for late 2026 ranging from $0.14 to $0.15 per share. Institutional activity shows mixed sentiment with both position reductions and maintained stakes among major holders.
The ETF faces headwinds from bearish technical indicators while maintaining dividend distributions. Key risks include interest rate sensitivity and institutional selling pressure. The neutral oscillator reading suggests potential for stabilization, but the overall technical picture warrants caution for near-term positioning in this high-yield bond ETF.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →